Compile Data Set for Download or QSAR
maximum 50k data
Found 128 with Last Name = 'vakkalanka' and Initial = 'sk'
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM184555(US9150579, A1)
Affinity DataIC50:  13.8nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of phosp...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141416(US10668051, Compound Example 67 | US8921364, 67)
Affinity DataIC50:  20.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141416(US10668051, Compound Example 67 | US8921364, 67)
Affinity DataIC50:  20.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141426(US10668051, Compound Example 84 | US8921364, 84)
Affinity DataIC50:  20.8nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141426(US10668051, Compound Example 84 | US8921364, 84)
Affinity DataIC50:  20.8nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM184556(US9150579, B1)
Affinity DataIC50:  22.3nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of phosp...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141438(US10668051, Compound Example 104 | US8921364, 104)
Affinity DataIC50:  23.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141438(US10668051, Compound Example 104 | US8921364, 104)
Affinity DataIC50:  23nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM184554(US9150579, B)
Affinity DataIC50:  24.9nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of phosp...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141428(US10668051, Compound Example 87 | US8921364, 87)
Affinity DataIC50:  32.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141428(US10668051, Compound Example 87 | US8921364, 87)
Affinity DataIC50:  32.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141421(US10668051, Compound Example 78 | US8921364, 78)
Affinity DataIC50:  34.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141421(US10668051, Compound Example 78 | US8921364, 78)
Affinity DataIC50:  34.1nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141424(US10668051, Compound Example 82 | US8921364, 82)
Affinity DataIC50:  35.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141424(US10668051, Compound Example 82 | US8921364, 82)
Affinity DataIC50:  35.7nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141396(US10668051, Compound Example 7 | US8921364, 7)
Affinity DataIC50:  36.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141396(US10668051, Compound Example 7 | US8921364, 7)
Affinity DataIC50:  36.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM184559(US9150579, A)
Affinity DataIC50:  37.3nMT: 2°CAssay Description:The homogenous time resolved fluorescence (HTRF) assay allows detection of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of phosp...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141444(US10668051, Compound Example 114 | US8921364, 114)
Affinity DataIC50:  37.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141444(US10668051, Compound Example 114 | US8921364, 114)
Affinity DataIC50:  37.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM152937(US8993612, 20)
Affinity DataIC50:  39.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141442(US10668051, Compound Example 111 | US8921364, 111)
Affinity DataIC50:  47.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141442(US10668051, Compound Example 111 | US8921364, 111)
Affinity DataIC50:  47.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141419(US10668051, Compound Example 74 | US8921364, 74)
Affinity DataIC50:  48nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141419(US10668051, Compound Example 74 | US8921364, 74)
Affinity DataIC50:  48.0nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141425(US10668051, Compound Example 83 | US8921364, 83)
Affinity DataIC50:  48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141425(US10668051, Compound Example 83 | US8921364, 83)
Affinity DataIC50:  48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141418(US10668051, Compound Example 72 | US8921364, 72)
Affinity DataIC50:  48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141418(US10668051, Compound Example 72 | US8921364, 72)
Affinity DataIC50:  48.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141441(US10668051, Compound Example 108 | US8921364, 108)
Affinity DataIC50:  50.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141441(US10668051, Compound Example 108 | US8921364, 108)
Affinity DataIC50:  50.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM152932(US8993612, 6)
Affinity DataIC50:  51.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141448(US10668051, Compound Example 126 | US8921364, 126)
Affinity DataIC50:  52.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141448(US10668051, Compound Example 126 | US8921364, 126)
Affinity DataIC50:  52.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM152936(US8993612, 18)
Affinity DataIC50:  53.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141439(US10668051, Compound Example 106 | US8921364, 106)
Affinity DataIC50:  60nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141439(US10668051, Compound Example 106 | US8921364, 106)
Affinity DataIC50:  60nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141402(US10668051, Compound Example 28 | US8921364, 28)
Affinity DataIC50:  60.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141402(US10668051, Compound Example 28 | US8921364, 28)
Affinity DataIC50:  60.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141393(US10668051, Compound Example 1 | US8921364, 1)
Affinity DataIC50:  62.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141393(US10668051, Compound Example 1 | US8921364, 1)
Affinity DataIC50:  62.4nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141443(US10668051, Compound Example 113 | US8921364, 113)
Affinity DataIC50:  62.6nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141443(US10668051, Compound Example 113 | US8921364, 113)
Affinity DataIC50:  62.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141412(US10668051, Compound Example 56 | US8921364, 56)
Affinity DataIC50:  63.2nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141412(US10668051, Compound Example 56 | US8921364, 56)
Affinity DataIC50:  63.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141409(US10668051, Compound Example 49 | US8921364, 49)
Affinity DataIC50:  65.5nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141409(US10668051, Compound Example 49 | US8921364, 49)
Affinity DataIC50:  65.5nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141440(US10668051, Compound Example 107 | US8921364, 107)
Affinity DataIC50:  70.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEF-hand calcium-binding domain-containing protein 4B(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141440(US10668051, Compound Example 107 | US8921364, 107)
Affinity DataIC50:  70.3nMT: 2°CAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141411(US10668051, Compound Example 53 | US8921364, 53)
Affinity DataIC50:  72nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 128 total ) | Next | Last >>
Jump to: